Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 5Gynecologic 1Gastrointestinal 1Dermatologic 1

Conditions

Fallopian Tube Neoplasms 3Ovarian Neoplasms 2Carcinoma, Ovarian Epithelial 2Uterine Cervical Neoplasms 1Neoplasms 1Melanoma 1Carcinoma, Hepatocellular 1Breast Neoplasms, Male 1Breast Neoplasms 1Anxiety Disorders 1

Interventions

pembrolizumab 33Paclitaxel 27Cyclophosphamide 25Carboplatin 23olaparib 21Fulvestrant 15fludarabine 14Trastuzumab 14aldesleukin 13Docetaxel 13Early Intervention, Educational 12Surveys and Questionnaires 11veliparib 10palbociclib 10Methods 10Gemcitabine 10Blood Specimen Collection 10Nivolumab 9Flow Cytometry 9Biopsy 9Bevacizumab 9sargramostim 8niraparib 7liposomal doxorubicin 7Therapeutics 7Taxes 7Standard of Care 7Psychiatric Rehabilitation 7Magnetic Resonance Spectroscopy 7talazoparib 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Breast Neoplasms × Propranolol × Gynecologic × Clear all
NCT02013492 2022-12-06

Propranolol Hydrochloride in Treating Patients With Locally Recurrent or Metastatic Solid Tumors That Cannot Be Removed By Surgery

Ohio State University Comprehensive Cancer Center

Phase EARLY_PHASE1 Completed
1 enrolled
BreastDermatologicGastrointestinalGynecologic

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Carcinoma, Hepatocellular, Melanoma, Breast Neoplasms, Male

Data powered by HemOnc (CC BY 4.0) Colophon âš¡